

Accepted Manuscript

Title: Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism

Author: Craig I. Coleman, Alexander G.G. Turpie, Thomas J. Bunz, Jan Beyer-Westendorf

PII: S0002-9343(18)30202-X

DOI: <https://doi.org/10.1016/j.amjmed.2018.02.015>

Reference: AJM 14561

To appear in: *The American Journal of Medicine*



Please cite this article as: Craig I. Coleman, Alexander G.G. Turpie, Thomas J. Bunz, Jan Beyer-Westendorf, Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism, *The American Journal of Medicine* (2018), <https://doi.org/10.1016/j.amjmed.2018.02.015>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism

Craig I. Coleman, PharmD^{a,b}; Alexander G.G. Turpie, MD^c; Thomas J. Bunz, PharmD, PhD^d; Jan Beyer-Westendorf, MD^{e,f}

Institutions:

- a. Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA
- b. Evidence-Based Practice Center, Hartford Hospital, Hartford, CT, USA
- c. Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- d. Department of Pharmacoepidemiology, New England Health Analytics, LLC, Granby, CT, USA
- e. Thrombosis Research Unit, Department of Medicine I, Division Hematology, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany
- f. Kings Thrombosis Service, Department of Hematology, Kings College London, London, UK

* All authors had access to the data and participated in the writing, critical revision and decision to submit the manuscript.

Corresponding Author:

Craig I. Coleman, PharmD
Professor of Pharmacy Practice
University of Connecticut School of Pharmacy
69 North Eagleville Road, Unit 3092
Storrs, CT 06269, USA
860-972-2096
craig.coleman@hhchealth.org

Funding:

This study was supported by Bayer AG, Berlin, Germany. The funder had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Conflicts-of-Interest:

Dr. Coleman has received grant funding and consultancy honorarium from Bayer AG, Janssen Scientific Affairs LLC and Boehringer Ingelheim Pharmaceuticals Inc. Dr. Turpie has received speaker's honoraria and consultancy fees from, and participated in scientific advisory boards for, Bayer HealthCare Pharmaceuticals and Janssen Research and Development, LLC, and has been a consultant for Bayer HealthCare, Janssen Pharmaceutical Research and Development, Astellas, Portola and Takeda. Dr. Beyer-Westendorf has received research grants from Bayer AG, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Portola Pharmaceuticals, and has served as a consultant to and has received honoraria from Bayer AG, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Portola Pharmaceuticals, CSL Behring and Medscape. Dr. Bunz has no disclosures germane to this manuscript.

Download English Version:

<https://daneshyari.com/en/article/8944087>

Download Persian Version:

<https://daneshyari.com/article/8944087>

[Daneshyari.com](https://daneshyari.com)